Author

N. Bardeesy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 7

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Research Focus:cancer & tumor microenvironment· 5 Organism:mouse· 5 Organism:human· 4 Assay:proteomics· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2

Frequent Co-Authors

A. Matsui· 2 shared D. Fukumura· 2 shared D. G. Duda· 2 shared J. Chen· 2 shared K. Inoue· 2 shared K.-K. Wong· 2 shared L. Shi· 2 shared P. Huang· 2 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Matsui

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Protein interactome homeostasis through an N-recognin E3 ligase is a vulnerability in aneuploid cancer

M. Kathiresan, S. Animesh, R. Morris, J. Kreuzer, P. Krushna, L. Shi, J. Merritt, X. Yin, C. H. Benes, N. Bardeesy, W. Haas

The paper identifies UBR4 as a critical mediator of protein interactome homeostasis in aneuploid cancers, showing its inactivation causes proteotoxic stress and convergence of copy number and protein levels.

bioRxiv · May 4, 2023 · PreprintCancer Biology

In vivo metabolomics identifies CD38 as an emergent vulnerability in LKB1-mutant lung cancer

J. Deng, D. H. Peng, D. Fenyo, Y. Hao, A. Lopez, D. Levin, M. Meynardie, M. Quinteros, M. Ranieri, S. Sahu, S. Lau, E. Shum, V. Velcheti, S. R. Punekar, N. Rekhtman, , K.-K. Wong

The paper identifies CD38 as a therapeutic target in LKB1-mutant lung cancer through in vivo metabolomics and shows that targeting CD38 inhibits tumor growth.

bioRxiv · Apr 18, 2023 · PreprintCancer Biology

Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy

J. Chen, Z. Amoozgar, X. LIU, S. Aoki, Z. Liu, S. Shin, A. Matsui, Z. Pu, P.-J. Lei, M. Datta, L. Zhu, Z. Ruan, L. Shi, D. Staiculescu, K. Inoue, , D. G. Duda

This paper shows that combining chemotherapy with CTLA-4 blockade reprograms the immune microenvironment of intrahepatic cholangiocarcinoma, enhancing the effectiveness of anti-PD1 therapy.

bioRxiv · Jan 26, 2023Cancer Biology

IFNA pathway drives the more aggressive phenotype of KRASG12D-mutant pancreatic ductal adenocarcinomas via IFNAR1/STAT3 activation

D. G. Duda, K. Inoue, D. H. Schanne, A. Matsui, P. Lei, S. Klein, S. Aoki, H. Taniguchi, H. Kikuchi, J. Chen, Z. Liu, S. Q. Tsai, T. C. Schmidt, M. Iwasaki, G. Geidel, , N. Bardeesy

The paper shows that the IFNA pathway promotes aggressive KRASG12D-mutant pancreatic ductal adenocarcinomas through IFNAR1/STAT3 activation and identifies IFNAR1 inhibition as a potential therapeutic strategy.

bioRxiv · Jun 29, 2022 · PreprintCancer Biology

Loss of Smad4 promotes aggressive lung cancer metastasis by de-repression ofPAK3 via miRNA regulation

X. Tan, L. Tong, L. Li, J. Xu, S. Xie, L. Ji, J. Fu, Q. Liu, S. Shen, Y. Liu, Y. Xiao, F. Gao, R. E. Moses, N. Bardeesy, Y. Wang, , X. Li

This study shows that Smad4 loss promotes lung cancer metastasis by upregulating PAK3 through miRNA regulation, suggesting Smad4 LOF as a prognostic marker and therapeutic target.

bioRxiv · Apr 29, 2021Cancer Biology

Oncogenic PKA signaling stabilizes MYC oncoproteins via an aurora kinase A-dependent mechanism

G. K. L. Chan, S. Maisel, Y. C. Hwang, R. R. B. Wolber, P. Vu, K. C. Patra, M. Bouhaddou, H. L. Kenerson, R. S. Yeung, D. L. Swaney, N. J. Krogan, R. E. Turnham, J. D. Scott, K. J. Riehle, N. Bardeesy, J. D. Gordan

This study identifies two PKA-driven oncogenic mechanisms, showing AURKA stabilizes MYC oncoproteins through a PIM2-mediated feedback loop, and suggests CD-532 as a potential therapeutic target.

bioRxiv · Apr 16, 2021Cancer Biology

Nuclear GSK-3β and Oncogenic KRas Promote Expansion of Terminal Duct Cells and the Development of Intraductal Papillary Mucinous Neoplasm

L. Ding, K. Roeck, C. Zhang, B. Zidek, E. Rodman, Y. G. Hernandez-Barco, J.-S. Zhang, W. R. Bamlet, A. L. Oberg, L. Zhang, N. Bardeesy, H. Li, D. D. Billadeau

This study identifies Aqp5 as a key factor in IPMN development using a novel mouse model, linking nuclear GSK-3β and oncogenic KRas to terminal duct cell expansion.

bioRxiv · Jul 14, 2020 · PreprintCancer Biology